Corcept Therapeutics (CORT) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $22.9 million.
- Corcept Therapeutics' Share-based Compensation rose 4208.79% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.5 million, marking a year-over-year increase of 3974.98%. This contributed to the annual value of $61.4 million for FY2024, which is 2536.58% up from last year.
- Per Corcept Therapeutics' latest filing, its Share-based Compensation stood at $22.9 million for Q3 2025, which was up 4208.79% from $19.0 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Share-based Compensation registered a high of $22.9 million during Q3 2025, and its lowest value of $10.1 million during Q1 2021.
- Moreover, its 5-year median value for Share-based Compensation was $11.9 million (2023), whereas its average is $13.7 million.
- In the last 5 years, Corcept Therapeutics' Share-based Compensation plummeted by 417.42% in 2022 and then skyrocketed by 6476.72% in 2025.
- Quarter analysis of 5 years shows Corcept Therapeutics' Share-based Compensation stood at $10.8 million in 2021, then decreased by 2.67% to $10.5 million in 2022, then grew by 24.18% to $13.1 million in 2023, then rose by 28.56% to $16.8 million in 2024, then skyrocketed by 36.22% to $22.9 million in 2025.
- Its Share-based Compensation stands at $22.9 million for Q3 2025, versus $19.0 million for Q2 2025 and $21.8 million for Q1 2025.